Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The JointJYNT +0.97%65 Cash-to-Debt is 10.88 as of Jun. 2026, which is 757% above its 10-year median of 1.27. GuruFocus rates JYNT with a GF Score™ of 65/100 and a GF Value™ of $11.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 671 Healthcare Providers & Services companies, The Joint ranks better than 81.52% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. The Joint's cash to debt ratio for the quarter that ended in Jun. 2026 was 10.88.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, The Jointcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for The Joint's Cash-to-Debt or its related term are showing as below:
JYNT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.37 Med: 1.27 Max: 31.51
Current: 10.88
During the past 13 years, The Joint's highest Cash to Debt Ratio was 31.51. The lowest was 0.37. And the median was 1.27.
JYNT's Cash-to-Debt is ranked better than 81.52% of 671
companies
in the Healthcare Providers & Services industry
Industry Median: 0.79
vs JYNT: 10.88
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
The Joint Cash-to-Debt Related Terms
The Joint Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for The Joint's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Care Facilities subindustry, The Joint's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where The Joint's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Joint (JYNT) has a Cash-to-Debt of 10.88 as of Jun. 2026. This is 757% above median its historical median of 1.27. Over the past decade, The Joint's Cash-to-Debt has ranged from 0.37 to 31.51. According to the industry distribution chart, The Joint ranks #124 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 18.5%.
Is The Joint's Cash-to-Debt too high?
The Joint's current Cash-to-Debt of 10.88 is 757% above median its 10-year median of 1.27. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 31.51. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. The Joint's value of 10.88 is 1277.2% above this industry median. Based on the distribution chart, The Joint ranks #124 out of 671 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, The Joint has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's Cash-to-Debt compare to PARK and WW?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #124 out of 671 companies for Cash-to-Debt. This places The Joint in the top 19% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.79. The Joint's value of 10.88 is 1277.2% above this benchmark. Historically, The Joint's own Cash-to-Debt has ranged from 0.37 to 31.51 over the past decade. While the company's 10-year median is 1.27 vs. the industry median of 0.79, The Joint has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Joint's current Cash-to-Debt of 10.88 is 1277.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current Cash-to-Debt is 10.88, which is 757% above median its own 10-year median of 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.55, compared to a current price of $8.28 — trading 28.3% below its estimated fair value. The current Cash-to-Debt is 10.88, which is 757% above median its 10-year median of 1.27 and 1277.2% above the Healthcare Providers & Services industry median of 0.79. The Joint's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For The Joint (JYNT), the current Cash-to-Debt is 10.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.28 is trading 28.3% below its estimated GF Value™ of $11.55.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
Cash-to-Debt: 10.88 (757% above median its 10-year median of 1.27)
GF Value™: $11.55 vs. price of $8.28 (28.3% below fair value)
Industry Position: 1277.2% above the Healthcare Providers & Services median (#124 of 671)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
65GF Score
Get the complete analysis for JYNT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
